HKEX: 3692
Voluntary announcement - update on the marketing authorization status of aumolertinib in the eu
View original source (HKEXnews)
Earlier from Hansoh Pharmaceutical
- Hansoh Pharmaceutical: PHARMA ANNOUNCES PIVOTAL PHASE 3 CLINICAL TRIAL OF HS-10374 IN THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS MET THE CO-PRIMARY ENDPOINTS
- Hansoh Pharmaceutical: WCLC 2026 | HANSOH PHARMA ANNOUNCES PROFFERED ORAL PRESENTATION OF PHASE I STUDY DATA OF HS-10370 COMBINED WITH ADEBRELIMAB AND CHEMOTHERAPY IN ADVANCED KRAS G12C-MUTATED NSCLC
- Hansoh Pharmaceutical: 2026 WCLC | HANSOH PHARMA ANNOUNCES INTERIM RESULTS FROM PHASE 3 ARTEMIS-008 STUDY OF RISVUTATUG REZETECAN (HS-20093) IN PATIENTS WITH RELAPSED SMALL CELL LUNG CANCER
- Hansoh Pharmaceutical: BIOLOGICS LICENSE APPLICATION OF RISVUTATUG REZETCAN (HS-20093) FOR INJECTION FOR SMALL CELL LUNG CANCER ACCEPTED BY THE NMPA